DE69922804D1 - USE OF POLYMERS OF HYALURONIC ACID FOR THE MUCOSAL RELEASE OF VACCINES AND ADJUVANTIES - Google Patents

USE OF POLYMERS OF HYALURONIC ACID FOR THE MUCOSAL RELEASE OF VACCINES AND ADJUVANTIES

Info

Publication number
DE69922804D1
DE69922804D1 DE69922804T DE69922804T DE69922804D1 DE 69922804 D1 DE69922804 D1 DE 69922804D1 DE 69922804 T DE69922804 T DE 69922804T DE 69922804 T DE69922804 T DE 69922804T DE 69922804 D1 DE69922804 D1 DE 69922804D1
Authority
DE
Germany
Prior art keywords
hyaluronic acid
adjuvanties
vaccines
polymers
mucosal release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69922804T
Other languages
German (de)
Other versions
DE69922804T2 (en
Inventor
Derek O'hagan
Alessandra Pavesio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia Farmaceutici SpA
Novartis Vaccines and Diagnostics Inc
Original Assignee
Fidia Advanced Biopolymers SRL
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Advanced Biopolymers SRL, Chiron Corp filed Critical Fidia Advanced Biopolymers SRL
Application granted granted Critical
Publication of DE69922804D1 publication Critical patent/DE69922804D1/en
Publication of DE69922804T2 publication Critical patent/DE69922804T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the compositions, as well as methods of immunization using the same.
DE69922804T 1998-06-01 1999-05-28 USE OF POLYMERS OF HYALURONIC ACID FOR THE MUCOSAL RELEASE OF VACCINES AND ADJUVANTIES Expired - Lifetime DE69922804T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8759698P 1998-06-01 1998-06-01
US87596P 1998-06-01
PCT/US1999/012105 WO1999062546A1 (en) 1998-06-01 1999-05-28 Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants

Publications (2)

Publication Number Publication Date
DE69922804D1 true DE69922804D1 (en) 2005-01-27
DE69922804T2 DE69922804T2 (en) 2005-12-15

Family

ID=22206133

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69922804T Expired - Lifetime DE69922804T2 (en) 1998-06-01 1999-05-28 USE OF POLYMERS OF HYALURONIC ACID FOR THE MUCOSAL RELEASE OF VACCINES AND ADJUVANTIES

Country Status (8)

Country Link
EP (1) EP1082135B1 (en)
JP (2) JP4610735B2 (en)
AT (1) ATE285250T1 (en)
AU (1) AU755465C (en)
CA (1) CA2332455C (en)
DE (1) DE69922804T2 (en)
ES (1) ES2235489T3 (en)
WO (1) WO1999062546A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002041877A1 (en) 2000-10-24 2002-05-30 Clear Solutions Biotech, Inc. Sodium hyaluronate microspheres
DE10064219B9 (en) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Novel pharmaceutical composition containing fentanyl and / or its derivatives
US20020192205A1 (en) * 2001-05-11 2002-12-19 Francis Michon Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci
US7238338B1 (en) 2001-06-22 2007-07-03 Triumf System and method for the large scale labeling of compounds with radiohalogens
FR2847818B1 (en) * 2002-11-28 2008-04-04 Agro Ind Rech S Et Dev Ard PHARMACEUTICAL COMPOSITION BASED ON HYALURONIC ACID
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
NZ567817A (en) * 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
JP2009209086A (en) * 2008-03-04 2009-09-17 Masami Moriyama Mucous membrane administration-type vaccine
JP2011057605A (en) * 2009-09-09 2011-03-24 Masami Moriyama Vaccine to be applied to mucous membrane

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
IT1247472B (en) * 1991-05-31 1994-12-17 Fidia Spa PROCESS FOR THE PREPARATION OF MICROSPHERES CONTAINING BIOLOGICALLY ACTIVE COMPONENTS.
JP3109886B2 (en) * 1991-12-13 2000-11-20 デンカ生研株式会社 Nasal vaccine
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant

Also Published As

Publication number Publication date
DE69922804T2 (en) 2005-12-15
ES2235489T3 (en) 2005-07-01
JP2002516876A (en) 2002-06-11
CA2332455C (en) 2012-08-14
JP4610735B2 (en) 2011-01-12
EP1082135B1 (en) 2004-12-22
EP1082135A1 (en) 2001-03-14
AU4410699A (en) 1999-12-20
ATE285250T1 (en) 2005-01-15
JP2010163432A (en) 2010-07-29
WO1999062546A1 (en) 1999-12-09
AU755465B2 (en) 2002-12-12
AU755465C (en) 2004-01-29
CA2332455A1 (en) 1999-12-09

Similar Documents

Publication Publication Date Title
AU4673099A (en) Use of bioadhesives and adjuvants for the mucosal delivery of antigens
MXPA01011047A (en) Neisseria genomic sequences and methods of their use.
NO20015073L (en) vaccinations
FR20C1016I1 (en)
CY1105963T1 (en) CAPSOMEPIDIAN VACCINE COMPOSITIONS AND METHODS OF USE
MXPA01003557A (en) Neisseria genomic sequences and methods of their use.
WO2001034801A3 (en) Recombinant gelatin in vaccines
DE60039198D1 (en) Adjuvant compositions for increasing the immune response to polynucleotide-based vaccines
CY1114643T1 (en) MODULAR CELLS NM-F9 (DSM ACC2606) AND NM-D4 (DSM ACC2605), USE OF THESE
DK1326633T3 (en) Composition comprising immunogenic microparticles
DE69912925D1 (en) VACCINE COMPOSITION AGAINST HERPES SIMPLEX VIRUS AND METHODS FOR USE
GB2386072A (en) Novel vaccine
ATE285250T1 (en) USE OF POLYMERS OF HYALURONIC ACID FOR MUCOSAL RELEASE OF VACCINES AND ADJUVANTS
WO2002024739A3 (en) Spas-1 cancer antigen
BR9704879A (en) Vaccine composition and use of a live cav virus
DE59101580D1 (en) SUPPORTED RECOMBINANT PROTEINS, METHOD FOR THE PRODUCTION AND USE AS IMMUNOGENIC AND VACCINE.
ATE503491T1 (en) IMPROVED ANTHRAX VACCINES AND DELIVERY METHODS
PT1272652E (en) HERPES VIRUS FOR IMMUNITY MODULATION
SE9903534D0 (en) Vaccine
WO2004098529A3 (en) Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
EP1667634A4 (en) Anthrax vaccine
DK1074266T3 (en) Live attenuated bacteria for use in vaccine
DK1159426T3 (en) Cloning and expression of Haemophilus somnus transferrin-binding proteins
ATE353226T1 (en) ADJUVANT COMPOSITION CONTAINING FHA OR AN FHA FRAGMENT IN FREE FORM
ATE350058T1 (en) MUTUALLY PROTECTIVE HERPES VIRUS COMPOSITION AND METHOD FOR THE PRODUCTION AND USE THEREOF

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EMERYV

Owner name: FIDIA FARMACEUTICI S.P.A., ABANO TERME, PADUA/PADO

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: FIDIA FARMACEUTICI S.P.A., ABANO TERME, PADUA/, IT

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US